ABT’s Freestyle Libre continuous glucose monitor, which has annualized sales of ~$5B (#msg-171723150) and is expected to reach $10B by 2028 (#msg-170908065), makes ABT a bona fide T2D investment play.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.